Summary
Extracellular amyloid β-peptide (Aβ) deposits in the brain are characteristic of Alzheimer’s disease. Proteolytic cleaving of amyloid precursor protein (APP) by β- and α-secretases generate these deposits. The cleavage by those secretases occurs predominantly in post-Golgi secretory and endocytic compartments and is influenced by cholesterol, indicating a role of the membrane lipid composition in APP processing. To analyze the function of glycosphingolipids (GSLs) in the proteolytic processing of APP and the generation of Aβ, we inhibited glycosylceramide synthase, the first enzyme in GSL biosynthesis pathway. The depletion of GSLs markedly reduced the secretion of endogenous APP in different cell types, including human neuroblastoma SH-SY5Y cells. Conversely, the addition of exogenous brain gangliosides to cultured cells increased the levels of both cellular and secreted APP. Importantly, depletion of GSLs strongly decreased the secretion of Aβ. Thus, enzymes involved in GSL metabolism might represent targets to inhibit Aβ production.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
4. References
Aguzzi A, Haass C (2003) Games played by rogue proteins in prion disorders and Alzheimer’s disease. Science, 302, 814–818.
Annaert W, de Strooper B (2002) A cell biological perspective on Alzheimer’s disease. Annu Rev Cell Dev Biol, 18, 25–51.
Chyung JH, Selkoe DJ (2003) Inhibition of receptor mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J.Biol.Chem, 278, 51035–51043.
Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci U S A, 101, 2070–2075.
Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ (1992) Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature, 357, 500–503.
Hartmann T (2001) Cholesterol, A beta and Alzheimer’s disease. Trends Neurosci, 24, S45–S48.
Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M, Ya-mamoto N, Michikawa M, Yoshikawa Y, Terao K, Matsuzaki K, Lemere CA, Selkoe DJ, Naiki H, Yanagisawa K (2004) A seed for Alzheimer amyloid in the brain. J Neurosci, 24, 4894–4902.
Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM (2004) The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron, 44, 227–238.
Ichikawa S, Nakajo N, Sakiyama H, Hirabayashi Y (1994) A mouse B16 melanoma mutant deficient in glycolipids. Proc Natl Acad Sci U S A, 91, 2703–2707.
Kok JW, Babia T, Filipeanu CM, Nelemans A, Egea G, Hoekstra D (1998) PDMP blocks brefeldin A-induced retrograde membrane transport from golgi to ER: evidence for involvement of calcium homeostasis and dissociation from sphingolipid metabolism. J Cell Biol, 142, 25–38.
Kolter T, Proia RL, Sandhoff K (2002) Combinatorial ganglioside biosynthesis. J Biol Chem, 277, 25859–25862.
Komori H, Ichikawa S, Hirabayashi Y, Ito M (1999) Regulation of intracellular ceramide content in B16 melanoma cells. Biological implications of ceramide glycosylation. J Biol Chem, 274, 8981–8987.
Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL (1990) Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A, 87, 1561–1565.
Koo EH, Squazzo SL (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem, 269, 17386–17389.
Koo EH, Squazzo SL, Selkoe DJ, Koo CH (1996) Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. J Cell Sci, 109, 991–998.
Mutoh T, Tokuda A, Inokuchi J, Kuriyama M (1998) Glucosylceramide synthase inhibitor inhibits the action of nerve growth factor in PC12 cells. J Biol Chem, 273, 26001–26007.
Naslavsky N, Shmeeda H, Friedlander G, Yanai A, Futerman AH, Barenholz Y, Taraboulos A (1999) Sphingolipid depletion increases formation of the scrapie prion protein in neuroblastoma cells infected with prions. J Biol Chem, 274, 20763–20771.
Opekarova M, Tanner W (2003) Specific lipid requirements of membrane proteins-a putative bottleneck in heterologous expression. Biochim Biophys Acta, 1610, 11–22.
Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer’s disease: the cholesterol connection. Nat Neurosci, 6, 345–351.
Rosenwald AG, Pagano RE (1994) Effects of the glucosphingolipid synthesis inhibitor, PDMP, on lysosomes in cultured cells. J Lipid Res, 35, 1232–1240.
Sawamura N, Ko M, Yu W, Zou K, Hanada K, Suzuki T, Gong JS, Yanagisawa K, Michikawa M (2004) Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J Biol Chem, 279, 11984–11991.
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev, 81, 741–766.
Simons K, Ehehalt R (2002) Cholesterol, lipid rafts, and disease. J Clin Invest, 110, 597–603.
Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (1990) Evidence that beta-amyloid protein in Alzheimer’s disease is not derived by normal processing. Science, 248, 492–495.
Sprong H, Degroote S, Claessens T, van Drunen J, Oorschot V, Westerink BH, Hirabayashi Y, Klumperman J, van der S P, van Meer G (2001b) Glycosphin-golipids are required for sorting melanosomal proteins in the Golgi complex. J Cell Biol, 155, 369–380.
Sprong H, van der Sluijs P., van Meer G (2001a) How proteins move lipids and lipids move proteins. Nat Rev Mol Cell Biol, 2, 504–513.
Steiner H, Haass C (2000) Intramembrane proteolysis by presenilins. Nat Rev Mol Cell Biol, 1, 217–224.
Sutterlin C, Doering TL, Schimmoller F, Schroder S, Riezman H (1997) Specific requirements for the ER to Golgi transport of GPI-anchored proteins in yeast. J Cell Sci, 110 (Pt 21), 2703–2714.
Walter J, Kaether C, Steiner H, Haass C (2001) The cell biology of Alzheimer’s disease: uncovering the secrets of secretases. Curr Opin Neurobiol, 11, 585–590.
Watanabe R, Funato K, Venkataraman K, Futerman AH, Riezman H (2002) Sphingolipids are required for the stable membrane association of glycosyl-phosphatidylinositol-anchored proteins in yeast. J Biol Chem, 277, 49538–49544.
Wolozin B (2004) Cholesterol and the biology of Alzheimer’s disease. Neuron, 41, 7–10.
Yanagisawa K, Odaka A, Suzuki N, Ihara Y (1995) GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer’s disease. Nat Med, 1, 1062–1066.
Zha Q, Ruan Y, Hartmann T, Beyreuther K, Zhang D (2004) GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol Psychiatry, 9, 946–952.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Tokyo
About this chapter
Cite this chapter
Tamboli, I.Y., Prager, K., Barth, E., Heneka, M., Sandhoff, K., Walter, J. (2006). Modulation of Proteolytic Processing by Glycosphingolipids Generates Amyloid β-Peptide. In: Hirabayashi, Y., Igarashi, Y., Merrill, A.H. (eds) Sphingolipid Biology. Springer, Tokyo. https://doi.org/10.1007/4-431-34200-1_25
Download citation
DOI: https://doi.org/10.1007/4-431-34200-1_25
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-34198-7
Online ISBN: 978-4-431-34200-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)